Body fluids

THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY

Retrieved on: 
Thursday, November 19, 2020

Daxors BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients capillary leak rate via its albumin tracer in addition to 98% accurate measure of plasma and red cell volume.

Key Points: 
  • Daxors BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients capillary leak rate via its albumin tracer in addition to 98% accurate measure of plasma and red cell volume.
  • Daxor is the global leader in blood volume measurement technology, utilized by major hospitals in the United States.
  • Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation.
  • We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.

Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study

Retrieved on: 
Friday, November 6, 2020

Fexuprazan is a potassium-competitive acid blocker (P-CAB), which reversibly blocks the proton pump that secretes gastric acids from the stomach wall.

Key Points: 
  • Fexuprazan is a potassium-competitive acid blocker (P-CAB), which reversibly blocks the proton pump that secretes gastric acids from the stomach wall.
  • The bridging study assessed pharmacokinetic and pharmacodynamic profiles of Fexuprazan in healthy Korean, Caucasian, and Japanese adults at the Seoul National University Hospital.
  • These study results are expected to accelerate our partnership efforts to quickly commercialize Fexuprazan in global markets, including the US and Europe."
  • The study results showed that Fexuprazan has 99% cure rate after 8 weeks of treatment and confirmed it is well-tolerate.

Grand Strand Hospitals Choose New Blood Provider

Retrieved on: 
Thursday, November 5, 2020

The Blood Connection (TBC), a Greenville, SC based community blood center, became the exclusive blood provider for Grand Strand Regional Medical Center and Conway Medical Center on October 1, 2020.

Key Points: 
  • The Blood Connection (TBC), a Greenville, SC based community blood center, became the exclusive blood provider for Grand Strand Regional Medical Center and Conway Medical Center on October 1, 2020.
  • This new relationship will impact thousands of residents by providing live-saving blood products to the Grand Strand region through the support of the community.
  • I cannot emphasize enough how important it is for the community to support its local blood center by donating blood.
  • When you donate blood with The Blood Connection, you are ensuring your neighbors will have the blood products needed to save lives every day.

Global Hematology and Coagulation (Lab-based and Decentralized) Markets, 2019-2020 & Forecast to 2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 3, 2020

Hematology and Coagulation Markets (Lab-based and Decentralized Markets) examines the current state of two growing testing markets.

Key Points: 
  • Hematology and Coagulation Markets (Lab-based and Decentralized Markets) examines the current state of two growing testing markets.
  • The report contains some discussion of COVID-19 as it relates to the hematology and coagulation markets.
  • Coagulation testing, including d-dimer, is considered to be a growing indicator of the impact and clinical outcomes of patients with COVID-19.
  • The evaluation of the global market for coagulation tests (lab-based and all POC) includes d-dimer as a segment in the market.

Alison Rose Foundation Announces First Donation of $25,000 to Support Research of Amniotic Fluid Embolism (AFE)

Retrieved on: 
Thursday, October 22, 2020

BUFFALO, New York, Oct. 22, 2020 /PRNewswire/ -- The Alison Rose Foundation is pleased to announce its first major charitable contribution in the amount of $25,000 to the Amniotic Fluid Embolism (AFE) Foundation to further research efforts of amniotic fluid embolism, a rare and often-fatal birth complication.

Key Points: 
  • BUFFALO, New York, Oct. 22, 2020 /PRNewswire/ -- The Alison Rose Foundation is pleased to announce its first major charitable contribution in the amount of $25,000 to the Amniotic Fluid Embolism (AFE) Foundation to further research efforts of amniotic fluid embolism, a rare and often-fatal birth complication.
  • The announcement comes on Alison Rose Waclawek's birthday, who the Alison Rose Foundation was created to honor after her tragic passing.
  • "We support the mission of the AFE Foundation and share in a united goal to one day prevent anyone from having to experience this devastating birth complication.
  • Nothing will replace the light that Alison brought to this world; being able to commemorate important moments, like her birthday, helps to keep her spirit alive."

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Nebraska

Retrieved on: 
Wednesday, October 21, 2020

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Omaha to collect standard plasma from healthy donors.

Key Points: 
  • BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Omaha to collect standard plasma from healthy donors.
  • Plasma is a lifeline for thousands of people with rare, chronic and complex diseases, and we are excited to open the first BioLife plasma collection center in Nebraska.
  • To learn more about BioLife Plasma Services, the donation process, and to schedule an appointment, please visit the BioLife website.
  • BioLife Plasma Services is an industry leader in the collection of high-quality plasma that is processed into life-saving plasma-based therapies.

Bio Products Laboratory Receives Triangle Business Journal's Fast 50 Award

Retrieved on: 
Monday, October 19, 2020

DURHAM, N.C., Oct. 19, 2020 /PRNewswire/ -- Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina, and worldwide headquarters and manufacturing facilities in Elstree, UK, has been recognized as a Fast 50 company by the Triangle Business Journal.

Key Points: 
  • DURHAM, N.C., Oct. 19, 2020 /PRNewswire/ -- Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina, and worldwide headquarters and manufacturing facilities in Elstree, UK, has been recognized as a Fast 50 company by the Triangle Business Journal.
  • This award recognizes BPL as one of the Triangle's 50 fastest growing privately held companies.
  • The Fast 50 winners were selected and ranked based on revenue growth in the preceding three years, as analyzed by a third-party firm.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/bio-products-laboratory-receives...
    SOURCE Bio Products Laboratory Inc.

Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021

Retrieved on: 
Monday, October 19, 2020

The initial order, planned to be supplied during the beginning of 2021, is sufficient to treat approximately 500 hospitalized patients.

Key Points: 
  • The initial order, planned to be supplied during the beginning of 2021, is sufficient to treat approximately 500 hospitalized patients.
  • This initial supply is expected to generate approximately $3.4 million in revenue for Kamada during the first quarter of 2021.
  • The companies U.S. clinical development of a plasma-derived IgG product as a potential COVID-19 treatment is expected to begin in early 2021 pending IND acceptance.
  • The Companys flagship product is GLASSIA, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. FDA.

PlasmaSaves.org Helps Collect Convalescent Plasma to Fight COVID-19

Retrieved on: 
Wednesday, October 14, 2020

Anyone who has recovered from COVID-19 is potentially eligible to receive a monetary contribution from PlasmaSaves.org for their time spent donating their convalescent plasma.

Key Points: 
  • Anyone who has recovered from COVID-19 is potentially eligible to receive a monetary contribution from PlasmaSaves.org for their time spent donating their convalescent plasma.
  • The plasma donated will not only help all communities with people battling COVID-19, but will aid in plasma research.
  • In recent months, convalescent plasma has emerged as a promising way to help the immune systems of those with COVID-19.
  • By offering a monetary incentive, PlasmaSaves.org hopes to attract even more people to donate their convalescent plasma.

Worldwide Industry for Blood Transfusion Diagnostics to 2027 - Strategic Recommendations for New Entrants - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 13, 2020

The "Blood Transfusion Diagnostics - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Transfusion Diagnostics - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • According to the report, the Global blood Transfusion Diagnostics Market accounted for $4.0 billion in 2019 and is expected to reach $7.56 billion by 2027, growing at a CAGR of 8.3% during the forecast period.
  • Blood transfusion is the method of transferring blood or blood products from one person to another.
  • Blood transfusion diagnostics play a crucial role in blood transfusion to avoid infection to both the receiver and donor.